Literature DB >> 8882628

Mechanisms of block of a human cloned potassium channel by the enantiomers of a new bradycardic agent: S-16257-2 and S-16260-2.

E Delpón1, C Valenzuela, O Pérez, L Franqueza, P Gay, D J Snyders, J Tamargo.   

Abstract

1. The effects of S-16257-2 (S57) and S-16260-2 (R60), the two enantiomers of a new bradycardic agent, were studied on human cloned K+ channels (hKv1.5) stably expressed in a mouse L cell line using the whole-cell configuration of the patch-clamp technique. 2. S57 and R60 did not modify the sigmoidal activation time course of the current but reduced the amplitude and increased the rate of the decay of the current during the application of depolarizing pulses. Both, S57 and R60 produced a concentration-dependent block of hKv1.5 channels with apparent KD values of 29.0 +/- 1.9 microM and 40.9 +/- 4.0 microM, respectively. Thus, S57 was 1.4 fold more potent than R60 in blocking hKv1.5 channels. 3. The blockade produced by S57 and R60 was voltage-dependent and increased steeply between -30 and 0 mV, which corresponded with the voltage range for channel opening. This result indicated that both enantiomers block the hKv1.5 channels, preferentially, when they are in the open state. Between 0 and +60 mV the blockade exhibited a shallow voltage-dependence which was described by an electrical distance of 0.18 +/- 0.002 and 0.19 +/- 0.004 for S57 and R60, respectively. 4. S57 and R60 also increased the rate of decline of the current during the application of depolarizing pulses. The time constant of such decline (tau Block) was faster in the presence of R60 than in the presence of S57 (16.2 +/- 1.5 ms vs. 24.0 +/- 2.6 ms; P < 0.01). The apparent association rate constants (k) were similar for S57 and R60 ((0.52 +/- 0.13) x 10(6) M-1 s-1 and (0.66 +/- 0.13) x 10(6) M-1 s-1, respectively), whereas the dissociation rate constant (l) was faster for R60 than for S57 (25.8 +/- 1.8 s-1 and 13.0 +/- 2.4 s-1, respectively). 5. Both enantiomers slowed the deactivation of the tail currents elicited upon repolarization to -40 mV, thus inducing a 'crossover' phenomenon. These results suggested that drug unbinding is required before hKv1.5 channels can close. 6. It is concluded that R60 and S57 produced a similar time- voltage- and state-dependent block of hKv1.5 channels that can be interpreted as open channel block by the charged form of each enantiomer. The main difference between R60 and S57 were linked to the apparent dissociation rate constants.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8882628      PMCID: PMC1909796          DOI: 10.1111/j.1476-5381.1996.tb16728.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  31 in total

1.  Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties.

Authors:  M Reiffen; W Eberlein; P Müller; M Psiorz; K Noll; J Heider; C Lillie; W Kobinger; P Luger
Journal:  J Med Chem       Date:  1990-05       Impact factor: 7.446

Review 2.  Quantitative structure/activity relations based on use-dependent block and repriming kinetics in myocardium.

Authors:  K R Courtney
Journal:  J Mol Cell Cardiol       Date:  1987-03       Impact factor: 5.000

3.  Gating mechanism of a cloned potassium channel expressed in frog oocytes and mammalian cells.

Authors:  G Koren; E R Liman; D E Logothetis; B Nadal-Ginard; P Hess
Journal:  Neuron       Date:  1990-01       Impact factor: 17.173

Review 4.  Specific bradycardic agents--a novel pharmacological class?

Authors:  W Kobinger; C Lillie
Journal:  Eur Heart J       Date:  1987-12       Impact factor: 29.983

5.  Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes.

Authors:  E Carmeliet
Journal:  Circ Res       Date:  1993-11       Impact factor: 17.367

6.  Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current.

Authors:  D Fedida; B Wible; Z Wang; B Fermini; F Faust; S Nattel; A M Brown
Journal:  Circ Res       Date:  1993-07       Impact factor: 17.367

Review 7.  Nonchiral, homochiral and composite chiral drugs.

Authors:  E J Ariëns
Journal:  Trends Pharmacol Sci       Date:  1993-02       Impact factor: 14.819

8.  Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents.

Authors:  Z Wang; B Fermini; S Nattel
Journal:  Circ Res       Date:  1993-12       Impact factor: 17.367

9.  Verapamil blocks a rapidly activating delayed rectifier K+ channel cloned from human heart.

Authors:  D Rampe; B Wible; D Fedida; R C Dage; A M Brown
Journal:  Mol Pharmacol       Date:  1993-09       Impact factor: 4.436

10.  A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression.

Authors:  D J Snyders; M M Tamkun; P B Bennett
Journal:  J Gen Physiol       Date:  1993-04       Impact factor: 4.086

View more
  4 in total

1.  Effects of a quaternary bupivacaine derivative on delayed rectifier K(+) currents.

Authors:  M Longobardo; T González; R Navarro-Polanco; R Caballero; E Delpón; J Tamargo; D J Snyders; M M Tamkun; C Valenzuela
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 2.  I f inhibition with ivabradine : electrophysiological effects and safety.

Authors:  Irina Savelieva; A John Camm
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

3.  Current-dependent block of rabbit sino-atrial node I(f) channels by ivabradine.

Authors:  Annalisa Bucchi; Mirko Baruscotti; Dario DiFrancesco
Journal:  J Gen Physiol       Date:  2002-07       Impact factor: 4.086

Review 4.  HCN Channels Modulators: The Need for Selectivity.

Authors:  Maria Novella Romanelli; Laura Sartiani; Alessio Masi; Guido Mannaioni; Dina Manetti; Alessandro Mugelli; Elisabetta Cerbai
Journal:  Curr Top Med Chem       Date:  2016       Impact factor: 3.295

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.